References

  1. Bollerslev J, et al. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015 Aug;173(2):G1-20.
  2. Brandi ML, et al. Management of Hypoparathyroidism: Summary Statement and Guidelines. The Journal of Clinical Endocrinology & Metabolism. 2016 Jun 1;101(6):2273–83.
  3. Chen K, et al. Clinical burden and healthcare resource utilization among patients with chronic hypoparathyroidism, overall and by adequately vs not adequately controlled disease: a multi-country chart review. Journal of Medical Economics. 2019 Jun 17;22(11):1141–52.
  4. Mannstadt M, et al. Hypoparathyroidism. Nat Rev Dis Primers. 2017 Aug 31;3:17055.
  5. Clarke BL, et al. Epidemiology and Diagnosis of Hypoparathyroidism. J Clin Endocrinol Metab. 2016 Jun 1;101(6):2284–2299.
  6. Khan AA, et al. Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. Eur J Endocrinol. 2019 Mar 01;180(3):1-22.
  7. Ascendis Pharma UK. Data on file. 2025.
  8. Shoback DM, et al. J Clin Endocrinol Metab. 2016;101(6):2300–12.
  9. National Cancer Institute. Bone Density. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/bone-density. [accessed October 2025].
  10. Medline Plus. Calcification. Available from: https://medlineplus.gov/ency/article/002321.htm [accessed October 2025].
  11. National Cancer Institute. Cognitive impairment. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cognitive-impairment. [accessed October 2025].
  12. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press; 2011.
  13. Qadeer HA, Bashire K. Physiology, Phosphate. StatPearls. 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560925/. [accessed October 2025].
  14. Goyal A, et al. Hypocalcemia. StatPearls. 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430912/. [accessed October 2025].
  15. Goyal R, Jialal I. Hyperphosphatemia. StatPearls. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551586/. [accessed October 2025].
  16. National Cancer Institute. Renal Failure. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/renal-failure. [accessed October 2025].
  17. Brod M, et al. Living with hypoparathyroidism: development of the Hypoparathyroidism Patient Experience Scale-Impact (HPES-Impact). Qual Life Res. 2021 Jan;30(1):277-291. doi: 10.1007/s11136-020-02607-1. Epub 2020 Aug 24. PMID: 32833143; PMCID: PMC7847873.
  18. Kontogeorgos G, et al. Low health-related quality of life in hypoparathyroidism and need for PTH analog. Endocrine Connections. 2022 Jan 10;11(1).
  19. Ascendis Pharma UK. Data on file. 2024.

Living with hypoparathyroidism

Woman in a garden

Impact of hypoparathyroidism on quality of life, physical functioning and psychological wellbeing

The burden of hypoparathyroidism (also known as hypopara) negatively impacts health-related quality of life, physical functioning, and psychological well-being, regardless of serum calcium levels. 2, 17, 18

Tab 1 content.

Tab 2 content.

Impact on quality of life

In a survey of 42 people living with hypopara, the respondents reported the following impacts on their daily life, mental health, activity and social life & relationships. 17

Daily Life 17

79%

were not able to do as many things around the home

43%

said that hypopara interferes with their ability to work

67%

were unable to do as much as they used to/want to

Mental Health 17

81%

felt anxious or had anxiety

64%

felt frustrated

62%

felt depressed or sad

Activity 17

76%

were not able to exercise in the same way

52%

are less active than they used to be/want to be

50%

were not as mobile (including ability to walk)

Social Life & Relationships 17

79%

were less able to engage in social activities

57%

were limited in the types of social activities they could do

43%

said hypopara affected their relationships with family

Find out more about living with hypopara

The insights used to inform this video have been taken from the qualitative responses gathered from a patient survey conducted in partnership with Ascendis Pharma UK and Parathyroid UK in 2024. 19 Data was reported on an aggregate level and data was provided anonymously.

Meet Laura who is living with hypoparathyroidism. In the video above, she shares her experiences of symptoms, diagnosis, treatment, and the impact hypopara has had on her life, along with her personal perspectives.

Meet Sabine and Fabienne who are both living with hypoparathyroidism. In the video above, they share their experiences of symptoms, diagnosis, treatment, and the impact hypopara has had on their lives, along with their personal perspectives.

Seeds of Change is a disease awareness initiative developed and funded by Ascendis Pharma UK Limited and supported by Parathyroid UK and Society for Endocrinology.

The content provided here is intended for informational purposes only and not for the purpose of rendering medical advice. Please consult your physician or other qualified healthcare provider with any questions regarding a medical condition or treatment and therapy.

Brought to you by
Ascendis Pharma logo
UK-COMM-2600007 | March 2026
© 2026 Seeds of Change
Contact Us
Privacy Policy
Cookie Statement
Terms of Use